Abstract
Hypotensive episodes in patients receiving heparin by means of injection, some of which cause death, are voluntarily reported to the Food and Drug Administration (FDA). Many cases occur in medical situations associated with hypotension, such as hemodialysis or pulmonary embolus. Such reports of hypotensive episodes and, unfortunately, of associated deaths increased dramatically from November 2007 through February 2008.1 Close cooperation among the FDA, the Centers for Disease Control and Prevention, pharmaceutical companies, and physicians led to the tracing of the problematic preparations of heparin to the Scientific Protein Laboratories' manufacturing operation in Changzhou, China. Consequently, by March 2008, exposures of . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
